Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    Nurse well-being
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    November 23, 2023
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    Oncology nurse education
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    November 10, 2023
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    Oncology nurse influence
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    November 03, 2023
    Filipino American History Month nurse standing next to flag
    Nurse empowerment
    Filipino American History Month Shines Light on the Contributions and Challenges of a Committed Community of Nurses
    October 16, 2023
    Explore Somatic Biomarker Testing Report Component Biomarker Testing
    Clinical practice
    Learn How to Read a Somatic Biomarker Testing Report
    October 06, 2023
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Research

    ASCO Annual Meeting

    Researchers Clarify Connection Between Night Shift Work Duration and the Risk of Colorectal Cancer

    Evidence already supports a connection between night shift work and an increased risk of colorectal cancer (CRC), but the mechanism has been difficult to pinpoint. In a study presented at the 2018 American Society of Clinical Oncology Annual Meeting, researchers evaluated the insulin receptor substrate (IRS) 1 and 2 proteins and presented the role they play in the connection of night shift work and CRC.

    June 03, 2018
    ASCO Annual Meeting

    Early Oncology Care Model Data Show Reduced Hospital Admissions

    Improving quality and reducing costs in a practice are two of the Oncology Care Model’s (OCM) key goals, and one of the best ways to achieve them is to reduce unnecessary emergency department (ED) visits and hospitalizations. During a study presented at the 2018 American Society of Clinical Oncology Annual Meeting, researchers described a campaign implemented to reach those objectives.

    June 02, 2018
    ASCO Annual Meeting

    Patients Report More Satisfaction With Multidisciplinary Care Versus Serial Care for Lung Cancer

    Despite the prevalence of multidisciplinary (MD) care for cancer, rigorous studies comparing it to serial care (SC) are lacking. To address the literature gap, researchers explored the use of MD versus SC for lung cancer and presented the findings at the 2018 American Society of Clinical Oncology Annual Meeting.

    June 02, 2018
    Study Finds That Safety Decreases as Electronic Health Record Capability Increases
    ASCO Annual Meeting

    Study Finds That Safety Decreases as Electronic Health Record Capability Increases

    More needs to be known about how communication challenges and documentation affect ambulatory oncology care. In a presentation on Saturday, June 2, at the 2018 American Society of Clinical Oncology Annual Meeting, researchers revealed study findings about how patient safety is directly affected by electronic health record (EHR) capability and satisfaction, clinician communication, and clinicians’ actions.

    June 02, 2018
    ASCO Annual Meeting

    Nurses Should Focus on Goal Setting and Shared Decision Making in Cancer Aftercare Conversations

    Goal setting and shared decision making are important components of aftercare for cancer survivors. In the results of a study published in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting, researchers shared their experience developing and pretesting a systematic conversation approach for nurses to tailor the aftercare needs and goals of cancer survivors.

    May 29, 2018
    ASCO Annual Meeting

    Organizational Learning and Perception Tied to Improved Patient Safety Culture

    Patient safety is an important focus for hospitals: protecting patients improves outcomes and quality of care, meets standards, and ensures payments and reimbursement. But what factors contribute to a culture of safety? Researchers assessed and analyzed the components of patient safety culture and published their study findings in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting.

    May 29, 2018
    ASCO Annual Meeting

    Study Quantifies Data on NPs and PAs Caring for Older Adults With Cancer

    Cancer is the most common diagnosis in adults older than 65 in the United States. As the older adult population increases and drives up malignancy diagnoses, nurse practitioners’ (NPs) and physician assistants’ (PAs) contributions to their care need to be better identified. In the results of a study published in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting, researchers reported on their exploration of the role of NPs and PAs in the oncology workforce.

    May 29, 2018
    national capital chapter
    Cancer healthcare advocacy

    National Capital Chapter Members Focus on Advocacy and Research Funding in DC

    In our nation’s capital, healthcare policy meetings occur weekly for various government and private organizations whose aim is to improve care and conditions for patients with cancer. The ONS National Capital Chapter members are involved in lobbying on the Hill and attending meetings about improving cancer care through the ONS Capitol Hill Gang.

    May 25, 2018
    ONS Congress

    Tips for Creating a Multidisciplinary Research Team Focused on Symptom Management

    Catherine Bender, PhD, RN, FAAN, of the University of Pittsburgh, and Amy Hoffman, PhD, RN, of Michigan State University, shared their experiences in building interdisciplinary research teams to assess symptom management during a session at the 43rd Annual Congress in Washington, DC.

    May 19, 2018
    ONS Congress

    The Power of a Nurse: The Mara Mogensen Flaherty Memorial Lectureship

    Margaret Bevans, PhD, RN, AOCN®, FAAN, program director and clinical nurse scientist at the National Institutes of Health’s Nursing Research and Translational Science department, detailed her own journey and empowered nurses to amplify their impact during her Mara Mogensen Flaherty Memorial lecture at the 43rd Annual Congress in Washington, DC.

    May 19, 2018

    Immunotherapy Opens New Frontiers in Lung Cancer Care

    The development of targeted therapies brought new progress to lung cancer treatment and research in the past 20 years, and new options will continue to be available in the future. Roy Herbst, MD, PhD, director of thoracic oncology research program at the Yale Comprehensive Cancer Center at Yale School of Medicine in New Haven, CT, spoke at the 43rd Annual Congress in Washington, DC, on new standards of care for non-small cell lung cancer (NSCLC), immunotherapy for NSCLC, and development of rational drug combinations using biomarkers.

    May 19, 2018
    ONS Congress

    Nurse Scientists Are Promoting the Future of Cancer Nursing Research at NINR and NCI

    Many programs at the National Cancer Institute (NCI) are focused on cancer research, and support for cancer- and treatment-related symptoms and toxicities crosses a number of National Institutes of Health (NIH) organizations. Martha Matocha, PhD, program director and team lead of the National Institute of Nursing Research (NINR), and Ann O’Mara, PhD, RN, FAAN, program officer at NCI, provided tips and opportunities for nurses and how they can conduct or participate in cancer research programs during a session at the 43rd Annual Congress in Washington, DC.

    May 17, 2018
    Huntington Disease May Hold Key to Novel Cancer Treatment
    Research

    Huntington Disease May Hold Key to Novel Cancer Treatment

    The mutated huntington (HTT) gene causes the body to generate a class of small molecules that are toxic to cancer cells but not most healthy cells, according to the results of a new study published in EMBO Reports. The researchers went as far as to call it a “super assassin against all tumor cells.”

    May 16, 2018
    How Aromatherapy With Essential Oils May Help Patients With Cancer
    Complementary therapy

    How Aromatherapy With Essential Oils May Help Patients With Cancer

    Aromatherapy has grown in popularity over the past few decades for improving sleep and mood and for reducing anxiety, but its first use dates back more than 5,000 years. The practice involves using essential (aromatic) oils, derived typically from steam distillation of plants, through application to the skin as a component of therapeutic massage or inhalation with vaporizers, inhalers, or hot water baths.

    May 14, 2018
    Childhood Obesity May Be a Factor in Increasing Cancer Rates in Young Adults
    Cancer risk factors

    Childhood Obesity May Be a Factor in Increasing Cancer Rates in Young Adults

    Although overall cancer rates are on the decline, 9 of the 20 most common cancers in the United States are increasing more frequently in young adults aged 20–44. And those same 9 cancers are among the 13 cancers that have clear ties to obesity. In a new study published in Obesity, a researcher makes the case for a connection between the two.

    May 09, 2018
    Evidence for Nephrotoxicity Prevention With Cisplatin Therapy Is Still Limited
    Treatment side effects

    Evidence for Nephrotoxicity Prevention With Cisplatin Therapy Is Still Limited

    Cisplatin chemotherapy is used alone or in combination to treat a variety of cancers, including ovarian, testicular, lung, cervical, bladder, head and neck, and gastric cancers as well as lymphoma, melanoma, and more. Although it offers options for many cancer types, its use may result in nephrotoxicity, a dose-limiting side effect. Use of hydration and diuretics may help reduce its incidence, but no standards or best practices are in place to guide those treatments.

    May 08, 2018
    FDA Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    On May 1, 2018, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

    May 03, 2018
    Regular Exercise May Improve Outcomes in Patients With Lung Cancer
    Research

    Regular Exercise May Improve Outcomes in Patients With Lung Cancer

    In addition to lowering cancer risk, regular exercise before lung cancer surgery may improve postoperative outcomes, especially in lung cancer, according to the results of a literature review published in the British Journal of Sports Medicine.

    May 02, 2018
    How Does Mentorship Help New Oncology Nurse Authors Get Published?
    Oncology nurse influence

    How Does Mentorship Help New Oncology Nurse Authors Get Published?

    Writing and publishing for the first time can be a daunting experience, but the Clinical Journal of Oncology Nursing (CJON) Writing Mentorship Program is a great opportunity for oncology nurses looking to publish their own work. The program pairs published nurses who share their experiences and expertise with ONS members who are new to the publishing process.

    May 01, 2018
    Insurer Group Warns Against Short-Term Health Plan Proposal; Medicaid Won’t Look the Same in 2019; Rapid Autopsy Programs Seek Clues to Cancer Within Hours of Death
    Health Policy

    Insurer Group Warns Against Short-Term Health Plan Proposal; Medicaid Won’t Look the Same in 2019; Rapid Autopsy Programs Seek Clues to Cancer Within Hours of Death

    Earlier in 2018, the Trump administration proposed a new rule that would permit Americans to buy short-term health insurance for up to 12 months, breaking from an Obama-era regulation that limited short-term health plans to a maximum of three months. To some, the proposed extension would potentially extend coverage to Americans interested in insuring themselves and their families. However, the America’s Health Insurance Plans group is on the other side of the argument, insisting that temporary plans—for any length of time—are no substitute to real coverage. Short-term plans are not covered by Affordable Care Act regulations, and it could lead to patients with pre-existing conditions being charged more for temporary insurance.

    April 30, 2018
    How DNA Revolutionized Oncology Care
    Genetics & genomics

    How DNA Revolutionized Oncology Care

    April 25, 2018, marks National DNA Day. Why the hype? National DNA Day commemorates the successful completion of the Human Genome Project in 2003, and the discovery of DNA's double helix in 1953. Without DNA, understanding the diseases and treatments for cancer would be nearly impossible. Genetics and genomics play huge roles in treating malignancy, and it’s crucial to the care of patients with cancer for oncology nurses to understand genetics and genomics.

    April 25, 2018
    Labs Differ Widely in BRCA Testing Protocols
    Genetics & genomics

    Labs Differ Widely in BRCA Testing Protocols

    An international survey of 86 genetic testing labs showed inconsistent protocols and standards for analyzing the BRCA1 or 2 cancer susceptibility genes and their variations. The results were reported in NPJ Genomic Medicine.

    April 18, 2018
    FDA Approves fostamatinib tablets for ITP
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fostamatinib Tablets for ITP

    On April 17, 2018, the U.S. Food and Drug Administration approved fostamatinib disodium hexahydrate tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

    April 17, 2018
    FDA Approves Everolimus for TSC-Associated Partial-Onset Seizures
    U.S. Food and Drug Administration (FDA)

    FDA Approves Everolimus for TSC-Associated Partial-Onset Seizures

    On April 10, 2018, the U.S. Food and Drug Administration (FDA) approved everolimus tablets for oral suspension for the adjunctive treatment of adult and pediatric patients aged 2-years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma.

    April 11, 2018
    Two Bacteria Species Connected to Certain Colon Cancers
    Research

    Two Bacteria Species Connected to Certain Colon Cancers

    Bacteroides fragilis and Escherichia coli appear to collaborate to promote hereditary and sporadic colon cancers, according to the results of studies published in Cell Host and Microbe and Science.

    March 21, 2018
    NIH Devotes Funding to Precision Research for Childhood Cancer
    Research

    NIH Funds Precision Research for Childhood Cancer; Will Congress Lift Medicaid Ban for Opioid Epidemic?; FDA-Approved Breast Cancer Test May Impact Oncology Nurses

    Cancer treatments aren’t one-size-fits-all, and they differ greatly depending on age.  As the leading cause of disease-related death for children, pediatric cancers pose a critical threat to this population. According to the National Institutes of Health (NIH), one reason pediatric cancer mortality rates persist is because there’s “limited knowledge” related to the biological mechanisms affecting childhood cancers. NIH-funded studies are breaking ground and uncovering new information about the genomics of pediatric cancers.

    March 12, 2018
    NCI Updates Cancer Trends Progress Report
    National Cancer Institute (NCI)

    NCI Updates Cancer Trends Progress Report

    The National Cancer Institute (NCI) has proactively shared new information and trends with the general public. Through its Cancer Trends Progress Report, NCI provides descriptions of research and data to help review past experiences and assist the agency in planning for future research funding.

    March 06, 2018
    ONS Advocacy
    Cancer health policy

    2018 U.S. Budget Agreement Contains Key Wins for ONS—Plus an Area of Concern

    The U.S. Congress continued its budget pattern in February, enacting another extension of the 2017 budget agreement into law on February 8, 2018. The current iteration of the budget law will raise caps on defense and non-defense spending over two years and keep the federal government running through March 23, but more importantly, it includes the following provisions of special interest to ONS.

    February 15, 2018
    Search the Literature to Critically Appraise Evidence
    Nursing evidence-based practice

    Search the Literature to Critically Appraise Evidence

    Changes in technology have brought about significant opportunities in how we identify and manage information. We have access to published research and clinical articles from thousands of journals to answer clinical questions. Finding the right information can be challenging, but building your skills in searching for evidence and synthesizing evidence is critical to becoming an evidence-based practice expert. Here’s how to proceed.

    February 13, 2018
    NIH: A Look Back at 2017 in Research
    Research

    NIH: A Look Back at 2017 in Research

    To plan for a strong future, one must understand the past. Reviewing the previous year’s accomplishments is always a good policy for reflection and improvement. It can help remind us of the accomplishments achieved in 12 short months. Such was the case at the National Institutes of Health (NIH), as director Francis Collins addressed the research achievements for 2017 in his opening blog.

    January 30, 2018
    FDA Clears Genomic Profiling Tests for Cancer Treatment
    U.S. Food and Drug Administration (FDA)

    FDA Clears Genomic Profiling Tests for Cancer Treatment

    Former National Institutes of Health (NIH) Director, Harold Varmus, when asked about cancer treatment, once said, “One of the major advances we’ve had as a result of cancer research is deep recognition of the complexity of cancer. It’s not one disease, it’s lots of different diseases. Every single cancer is different when you look at it on a genetic level.”

    January 29, 2018
    Public Health Consequences of E-Cigarettes
    Cancer risk factors

    National Academies Explain the Public Health Consequences of E-Cigarettes

    The National Academies of Sciences, Engineering, and Medicine recently released its latest report on the consequences of smoking, specifically related to electronic cigarettes. The report discusses the new effects of e-cigarettes as a public health hazard. According to the report, the effects of long-term e-cigarette use are still unknown, especially related to morbidity and mortality.

    January 25, 2018
    Immunotherapy Without Immune Cells
    Immunotherapy

    Immunotherapy Without Immune Cells May Be on the Horizon

    Researchers have generated immunotherapy in the laboratory using nonimmune cells. If the findings can be translated into treatment, it may reduce some of the immune-related adverse events that patients experience with today’s cancer immunotherapy treatments. The study was reported in Nature Chemical Biology.

    January 24, 2018
    drug holidays improve therapy for melanoma
    Research

    Drug Holidays May Improve Therapy for Treatment-Resistant Melanoma

    Taking an intentional drug holiday may improve patients’ response to reintroduction of treatment in drug-resistant melanoma, according to the results of a study published in Cancer Discovery.

    January 17, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Broadens Afatinib Indication to Previously Untreated, Metastatic NSCLC

    On January 12, 2018, the U.S. Food and Drug Administration (FDA) granted approval to afatinib for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

    January 15, 2018
    Most Americans Are Unaware of Key Cancer Risk Factors
    Research

    Most Americans Are Unaware of Key Cancer Risk Factors

    According to results from the first National Cancer Opinion Survey of 4,016 U.S. adults, the majority of Americans are unaware of several major risk factors for cancer, particularly obesity, which is the second-largest preventable cause of cancer in the United States, after smoking.

    January 10, 2018
    peripheral neuropathy from chemo
    Research

    Discovery of Peripheral Neuropathy Cause May Lead to Preventive Treatments

    Researchers have found that taxane chemotherapies such as paclitaxel impede a protein called Bclw, which leads to the side effect of peripheral neuropathy. The study results were published in Neuron.

    December 20, 2017
    Yoga for Cancer
    Complementary therapy

    Yoga May Improve Many Side Effects in Patients With Cancer

    December 15, 2017
    Infection Linked to Early Mortality in Post-ASCT Multiple Myeloma
    Multiple myeloma

    Infection Linked to Early Mortality in Post-ASCT Multiple Myeloma

    Patients with multiple myeloma are at increased risk for early death from infection after high-dose therapy and autologous stem cell transplantation (ASCT), according to the results of a study published in the American Journal of Hematology.

    December 13, 2017
    heart failure in women with breast cancer
    Breast cancer

    Heart Failure Affects Long-Term Survival Among Older Women With Breast Cancer

    Research has shown that women aged 65 and older who have breast cancer experience higher rates of heart failure compared to their age-matched counterparts, ranging from 29% of women with breast cancer who received no chemotherapy to 38% of women who received treatment with anthracyclines. However, little is known about the association between heart failure and long-term survival in older women with breast cancer, and it is unclear how the relative contribution of heart failure to mortality risk varies by breast cancer stage.

    December 11, 2017
    American Society of Hematology Annual Meeting

    Patients With MM Receiving PIs Need Herpes Zoster Prophylaxis

    Patients with multiple myeloma (MM) who receive proteasome inhibitors (PIs) are at an increased risk for herpes zoster infection, and National Comprehensive Cancer Network guidelines recommend antiviral prophylaxis for these patients. Researchers examined the use of and adherence to antiviral agents in this patient population. Siyang Leng, MD, at Columbia University Medical Center in Sunnyside, New York, discussed the findings at the ASH Annual Meeting.

    December 09, 2017
    blood test to detect cancer
    Research

    Blood Test May Detect Tumor-Derived DNA in Early-Stage Cancers

    Researchers have developed a test that detects tiny amounts of cancer-specific DNA in the blood and used it to accurately identify more than half of 138 people with early-stage colorectal, breast, lung, or ovarian cancers. The findings were published in Science Translational Medicine.

    December 06, 2017
    roles of oncology nurses in research
    Research

    NCI Advancements Are Pushing Research Forward for Patients

    Former U.S. Senator Arlen Specter (R-PA) put partisanship aside to support federal funding for biomedical research. And, while battling cancer himself, he spoke about the National Institutes of Health (NIH) and its crucial role in finding treatments and cures. “Health is our nation’s number one asset. Without your health, you can’t do anything. I believe medical research should be pursued with all possible haste to cure the diseases and maladies affecting Americans. I have said many times that the NIH is the crown jewel of the federal government—perhaps the only jewel of the federal government.”

    December 04, 2017
    Using Alternative Medicine Instead of Conventional Cancer Treatments Increases Risk of Death
    Research

    Using Alternative Medicine Instead of Conventional Cancer Treatments Increases Risk of Death

    A large study published in the Journal of the National Cancer Institute found that patients with nonmetastatic breast, lung, or colorectal cancer who chose to use only alternative medicine had substantially worse survival than patients who received conventional cancer treatment.

    November 29, 2017
    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer
    Lung Cancer

    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer

    Although cigarette use has long been linked to lung cancer, scientists have not understood how the earliest changes in lung cells developed. In a study published in Cancer Cell, researchers showed how cigarette smoke sensitized airway cells to genetic mutations that are known to cause lung cancers.

    November 22, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Sunitinib Malate for Adjuvant Treatment of Renal Cell Carcinoma

    On November 16, 2017, the U.S. Food and Drug Administration (FDA) approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

    November 17, 2017
    FDA Approves Obinutuzumab for Previously Untreated Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Obinutuzumab for Previously Untreated Follicular Lymphoma

    On November 16, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to obinutuzumab (Gazyva®, Genentech, Inc.) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).

    November 16, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Emicizumab-Kxwh for Bleeding in Patients With Hemophilia A With Factor VIII Inhibitors

    On November 16, 2017, the U.S. Food and Drug Administration (FDA) approved emicizumab-kxwh (Hemlibra®, Genentech, Inc.) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

    November 16, 2017
    New Imaging Shows Immunotherapy Results in Brain Cancer
    Immunotherapy

    New Imaging Better Shows Immunotherapy Results in Brain Cancer

    Researchers have developed a new approach for brain imaging that can better distinguish immune responses from tumor growth in people with glioblastoma. The findings were published in Proceedings of the National Academy of Sciences.

    November 15, 2017
    Medicinal Mushrooms in Patients With Cancer
    Complementary therapy

    Safety of Medicinal Mushrooms in Patients With Cancer

    Mushrooms have been valued for their health-promoting and medicinal effects for thousands of years. Research over the past few decades has focused on maitake (Grifola frondosa), reishi (Ganoderma lucidum), coriolus (Coriolus versicolor), shiitake (Lentinula edodes), and agaricus (Agaricus blazei), which are predominantly used in Asia.

    November 14, 2017
    • First page « First
    • Previous page
    • …
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Current page 8
    • Page 9
    • Page 10
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲